Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study.

In our data, patients who received bendamustine within 6 months before glofitamab treatment experienced significantly reduced PFS and showed a trend toward lower OS than those who had either been treated with bendamustine >6 months earlier or had no prior exposure to the drug ( Figure 3 G-H).

also in 53,322 other papers